# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $12 price ...
Chardan Capital analyst Keay Nakae maintains Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $7 price target.
Omega Therapeutics (NASDAQ:OMGA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of ...
HC Wainwright & Co. analyst Robert Burns reiterates Omega Therapeutics (NASDAQ:OMGA) with a Buy and maintains $12 price ...
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardles...
Piper Sandler analyst Edward Tenthoff reiterates Omega Therapeutics (NASDAQ:OMGA) with a Overweight and lowers the price tar...